What is Zacks Research’s Estimate for CRDF FY2027 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Research analysts at Zacks Research lowered their FY2027 EPS estimates for Cardiff Oncology in a report released on Monday, March 2nd. Zacks Research analyst J. Vandermosten now expects that the company will post earnings per share of ($0.75) for the year, down from their previous forecast of ($0.74). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 82.01%. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million.

A number of other brokerages also recently issued reports on CRDF. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Cardiff Oncology in a report on Wednesday, January 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Noble Financial began coverage on Cardiff Oncology in a report on Monday, January 5th. They issued an “outperform” rating and a $12.00 price target for the company. Wall Street Zen upgraded shares of Cardiff Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Piper Sandler reduced their price objective on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.

Cardiff Oncology Trading Down 2.6%

Shares of CRDF opened at $1.89 on Wednesday. The firm has a market capitalization of $129.20 million, a price-to-earnings ratio of -2.74 and a beta of 1.32. The firm’s fifty day simple moving average is $2.28 and its 200-day simple moving average is $2.24. Cardiff Oncology has a twelve month low of $1.48 and a twelve month high of $4.56.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CRDF. Franklin Resources Inc. purchased a new stake in Cardiff Oncology in the fourth quarter valued at approximately $3,388,000. Laurion Capital Management LP increased its holdings in shares of Cardiff Oncology by 37.2% in the 3rd quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock valued at $5,080,000 after acquiring an additional 668,590 shares during the period. Acorn Capital Advisors LLC raised its position in Cardiff Oncology by 39.3% in the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after purchasing an additional 553,317 shares during the last quarter. Flputnam Investment Management Co. raised its position in Cardiff Oncology by 1,008.8% in the 3rd quarter. Flputnam Investment Management Co. now owns 597,233 shares of the company’s stock valued at $1,230,000 after purchasing an additional 543,370 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in Cardiff Oncology by 441.5% during the 4th quarter. Millennium Management LLC now owns 194,420 shares of the company’s stock worth $546,000 after purchasing an additional 158,519 shares during the period. Institutional investors and hedge funds own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.